MOUNTAIN VIEW, CA (MARKET WIRE) Versartis, Inc., an emerging biotechnology company developing novel therapeutics for patients with metabolic diseases and endocrine disorders, announced positive results of the company's VRS-317, a once monthly form of human growth hormone, today in San Diego at ENDO 2010: The 92nd Annual Meeting of the Endocrine Society. During the meeting, the company also introduced 9 new members of its VRS-317 Clinical Advisory Board (CAB), which now comprises 14 renowned growth deficiency endocrinologists.